What VIDO-InterVac does best

Research excellence

• VIDO-InterVac is a world leader in developing vaccines and technologies against infectious diseases.

• Created in 1975, research collaborations have resulted in 80-plus U.S. patents and eight commercialized vaccines.  Six of these vaccines were world firsts. 

Protecting animals, Saving Lives

• Our vaccines have saved millions of dollars for the agricultural industry, making Canada more competitive internationally and enhancing global trade.

• Our research is driving the discovery of new vaccines that are transforming the future of public health.

Success through collaboration 

• VIDO-InterVac is open to academic teams and researchers from Canadian and international universities, commercial partners, research institutes and governments.

• Cutting-edge technology and facilities provide unparalleled opportunities for research.

News and Events

• Former VIDO-InterVac Director Dr. Lorne Babiuk Honored with Gairdner Wightman Award - Mar 21, 2012
• VIDO-InterVac Scientists, Dr. Alexander Zakhartchouk and Dr. Yan Zhou, receive funding from Canadian Swine Health Board - Feb 16, 2012
• Dr. Sylvia van den Hurk receives CIHR Grant for Subunit Respiratory Syncytial Virus Vaccine - Feb 16, 2012
• VIDO Annual Report 2011 - Jan 31, 2012

Current News and Events 

InterVac

The International Vaccine Centre (InterVac) is Canada's newest lab for protecting animals and humans against emerging infectious diseases:

• The new $140 million InterVac facility addresses the international shortage of facilities for studying Containment Level 3 (CL3) pathogens using diverse animal models.

• When InterVac becomes operational in 2012, it will be one of the largest and most advanced of its kind in North America.